Blog
Study evaluating intranasal anti-CD3 for treatment of Alzheimer’s disease published within the PNAS journal
10
Sep
Sep
Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, within the preeminent journal, Proceedings of the National Academy of Sciences (PNAS), that […]